Omnicell, Inc. (NASDAQ:OMCL) – Analysts at Cantor Fitzgerald issued their FY2019 earnings estimates for Omnicell in a research note issued to investors on Monday, April 29th, according to Zacks Investment Research. Cantor Fitzgerald analyst S. Halper forecasts that the company will post earnings of $2.01 per share for the year.
OMCL has been the subject of a number of other research reports. Zacks Investment Research lowered Omnicell from a “hold” rating to a “sell” rating in a research report on Friday, February 15th. Benchmark raised their price objective on Omnicell from $82.00 to $90.00 and gave the company a “buy” rating in a research report on Friday, April 26th. BidaskClub lowered Omnicell from a “hold” rating to a “sell” rating in a research report on Tuesday, April 23rd. Piper Jaffray Companies reiterated a “neutral” rating and issued a $70.00 price target on shares of Omnicell in a research report on Friday, February 8th. They noted that the move was a valuation call. Finally, Dougherty & Co lifted their price target on Omnicell from $78.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, March 7th. Five equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Omnicell currently has a consensus rating of “Buy” and a consensus target price of $79.89.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, April 25th. The company reported $0.61 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.23 by $0.38. The firm had revenue of $202.50 million during the quarter, compared to analyst estimates of $199.72 million. Omnicell had a return on equity of 11.10% and a net margin of 4.74%. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.29 earnings per share.
Several large investors have recently made changes to their positions in OMCL. Parallel Advisors LLC purchased a new position in shares of Omnicell in the first quarter valued at $28,000. C M Bidwell & Associates Ltd. bought a new stake in shares of Omnicell during the 1st quarter valued at $42,000. Nisa Investment Advisors LLC raised its stake in shares of Omnicell by 125.0% during the 1st quarter. Nisa Investment Advisors LLC now owns 540 shares of the company’s stock valued at $44,000 after purchasing an additional 300 shares during the period. Meeder Asset Management Inc. bought a new stake in shares of Omnicell during the 4th quarter valued at $35,000. Finally, Manchester Capital Management LLC bought a new stake in shares of Omnicell during the 1st quarter valued at $49,000. Institutional investors and hedge funds own 96.35% of the company’s stock.
In related news, Director Joanne B. Bauer sold 3,798 shares of Omnicell stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $81.72, for a total value of $310,372.56. Following the completion of the transaction, the director now owns 20,314 shares in the company, valued at $1,660,060.08. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Peter J. Kuipers sold 1,044 shares of the business’s stock in a transaction that occurred on Saturday, March 9th. The shares were sold at an average price of $44.34, for a total value of $46,290.96. Following the transaction, the chief financial officer now owns 56,873 shares of the company’s stock, valued at approximately $2,521,748.82. The disclosure for this sale can be found here. In the last quarter, insiders sold 199,464 shares of company stock valued at $15,226,091. 2.77% of the stock is currently owned by company insiders.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Further Reading: What are Bollinger Bands?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.